Back to top
more

Apyx Medical (APYX)

(Delayed Data from NSDQ)

$1.45 USD

1.45
58,368

-0.03 (-2.03%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.43 -0.02 (-1.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apyx (APYX) delivered earnings and revenue surprises of -46.15% and 1.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Owens & Minor (OMI) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 1.47% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of -237.50% and 4.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Apyx Medical (APYX) This Year?

by Zacks Equity Research

Here is how Apyx Medical (APYX) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

Apyx Medical (APYX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Apyx (APYX) delivered earnings and revenue surprises of 8.33% and 4.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Perrigo (PRGO) delivered earnings and revenue surprises of 16.67% and 0.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why You Should Add Humana (HUM) Stock to Your Portfolio Now

by Zacks Equity Research

Humana's (HUM) strength in Individual Medicare Advantage business and state-based contract wins are likely to be major tailwinds.

Here's Why Buying Brookdale (BKD) Stock is a Prudent Move Now

by Zacks Equity Research

For the second quarter, Brookdale (BKD) expects RevPAR growth to be in the range of 11.5-12%.

Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now

by Zacks Equity Research

The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.

The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights

by Zacks Equity Research

The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.

Is Abcam (ABCM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Abcam PLC Sponsored ADR (ABCM) and Apyx Medical (APYX) have performed compared to their sector so far this year.

Humana (HUM) Sees Insurance Costs at Upper Limit of Guidance

by Zacks Equity Research

Despite the rising demand for elective procedures, Humana (HUM) sticks to its earnings guidance.

Is Apyx Medical (APYX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Apyx Medical (APYX) and Haemonetics (HAE) have performed compared to their sector so far this year.

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -60% and 12.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ZimVie Inc. (ZIMV) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ZimVie Inc. (ZIMV) delivered earnings and revenue surprises of 525% and 9.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Apyx Medical (APYX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Apyx (APYX) delivered earnings and revenue surprises of -41.67% and 24.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apyx (APYX) delivered earnings and revenue surprises of -30.77% and 7.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Quidel (QDEL) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Quidel (QDEL) delivered earnings and revenue surprises of 25.65% and 21.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q1 Earnings Miss Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of -3.57% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Molina (MOH) to Join S&P 500 Driven by Medicare Performance

by Zacks Equity Research

Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.

Medtronic (MDT) Undertakes Investment to Advance STEM Education

by Zacks Equity Research

The Medtronic Foundation, solely funded by Medtronic plc (MDT), entered into 13 new partnerships to bridge the inequity in STEM education among underrepresented and underserved communities.

Ensign Group (ENSG) Up 7.4% in 3 Months: More Growth Ahead?

by Zacks Equity Research

Ensign Group (ENSG) is likely to keep growing on the back of Skilled services and impressive financial strength.

Molina Healthcare (MOH) Up 14.4% in 6 Months: Growth Ahead?

by Zacks Equity Research

Molina Healthcare (MOH) is likely to keep growing on the back of increasing membership and higher premium revenues.

Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits

by Zacks Equity Research

Select Medical Holdings (SEM) estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectations.

Earnings Preview: Apyx Medical (APYX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.